Clinical trials: Influenza, completed
Influenza, Human
Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Underlying Medical Conditions
Evaluate the safety, immune response and reactogenicity of aH5N1 vaccination in adult (18 through 60 years of age) and elderly (≥61 years of age) subjects with and without underlying medical conditions.
- Trial name
- NCT02091908
- Testing
- Novartis Investigational H5N1 vaccine, Novartis Seasonal Influenza Vaccine
- Where
- 6 sites in Germany
- Volunteers
- 540 people, healthy volunteers welcome
- Sponsor
- Seqirus
Healthy
Trial to Assess the Safety and Tolerability of the Liquid Formulation of CAIV-T in Healthy Children.
The purpose of this study is to determine the efficacy of the liquid formulation of CAIV-T against culture confirmed influenza illness in healthy children aged at least 6 months and less than 36 months.
- Trial name
- NCT00192400
- Testing
- CAIV-T
- Volunteers
- 2,160 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Influenza, Human, Critical Illness
A Pharmacokinetics Study of Favipiravir in Patients With Severe Influenza
Title: An adaptive study of the pharmacokinetics of favipiravir in patients with severe influenza Study Design: An open label, single group assignment, adaptive study to evaluate the pharmacokinetics of favipiravir in adult…
- Conditions
- Influenza, Human, Critical Illness, Influenza
- Trial name
- NCT03394209
- Testing
- Favipiravir, Oseltamivir 75Mg Capsule
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Capital Medical University
Seasonal Influenza, Hand, Foot and Mouth Disease
The Immunogenicity and Safety of the Vaccination of Inactivated Enterovirus 71 Vaccine and Seasonal Influenza Vaccine
The purpose of this study is to evaluate the Immunogenicity and safety of the simultaneously vaccination of Inactivated Enterovirus 71 Vaccine (EV71) and seasonal influenza vaccine(SIV)
- Trial name
- NCT04133584
- Testing
- EV71 +SIV, EV71, SIV
- Where
- China
- Volunteers
- 1,134 people
- Sponsor
- Zhejiang Provincial Center for Disease Control and Prevention
Influenza
Immunogenicity, Safety and Tolerability of a Trivalent Subunit Inactivated Vaccine in Healthy Subjects 50 Years and Above
Demonstrate non-inferiority of the post-vaccination (Day 22) Hemagglutination inhibition (HI) Geometric Mean Titers (GMTs) of trivalent, inactivated, subunit influenza vaccine (TIV) over the corresponding GMTs of the comparator…
- Trial name
- NCT01867021
- Testing
- Fluvirin(TIVf), Agriflu (TIV)
- Where
- 25 sites in Czechia, Philippines and 2 more
- Volunteers
- 2,902 people, healthy volunteers welcome
- Sponsor
- Novartis
Influenza
Evaluation of the Alere i Influenza A&B Nucleic Acid Amplification Versus Xpert Flu/RSV
The rapid and accurate detection of influenza virus in respiratory specimens is required for optimal management of patients with acute respiratory infections.
- Trial name
- NCT02846311
- Testing
- Flu Test
- Where
- France
- Volunteers
- 92 people
- Sponsor
- Fondation Hôpital Saint-Joseph
Influenza
Comparison of Three Licensed Influenza Vaccines
This study will evaluate in detail the way that the immune system responds to three different kinds of flu shots that are licensed in the United States.
- Trial name
- NCT03068949
- Testing
- FluBlok, Fluzone, FluCelVax
- Where
- United States
- Volunteers
- 413 people, healthy volunteers welcome
- Sponsor
- University of Rochester
Respiratory Syncytial Virus
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥50 Years of Age
The main purposes of Part A of this study are to evaluate the safety, tolerability, and immunogenicity of mRNA-1345 coadministered with a seasonal influenza vaccine (Afluria® Quadrivalent); to evaluate the impact of…
- Trial name
- RSVictory (NCT05330975)
- Testing
- mRNA-1345, Afluria® Quadrivalent, mRNA-1273.214
- Where
- 62 sites in United States
- Volunteers
- 3,317 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Influenza
A Phase I Clinical Trial for Inactivated Quadrivalent Influenza Vaccine (Split Virion) in Healthy Adults in China
Influenza is an acute respiratory disease caused by influenza viruses. There are three types of the virus including A, B and C. Both type A and type B viruses can cause acute febrile respiratory tract infection, characterized by…
- Trial name
- NCT02269007
- Testing
- inactivated quadrivalent influenza vaccine (split virion)
- Where
- China
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- Jiangsu Province Centers for Disease Control and Prevention
Influenza
Safety and Immunogenicity of 2 Commercially Available Influenza Vaccines in Children
This is a study of the safety and immunogenicity of three commercially available influenza vaccines in children.
- Trial name
- NCT00408395
- Testing
- Influenza vaccine
- Where
- Finland
- Volunteers
- 281 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Influenza
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Monovalent Pandemic H5N1 Vaccine in Adults
This trial will assess the immunogenicity and safety of GSK Biologicals' vaccine GSK1557484A, prepared from old concentrated monobulk material, in adults aged 18 to 64 years, when administered up to 5 years following production.
- Trial name
- NCT01416571
- Testing
- Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted
- Where
- United States
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Asthma
Trial to Compare the Safety, Tolerability and Efficacy of Influenza Virus Vaccine, (CAIV-T) With Influenza Virus in Children With Asthma
Trial to assess asthma exacerbation through to the end of the study; and to demonstrate that the efficacy over one season against culture-confirmed influenza-illness; and finally to assess the safety and tolerability of CAIV-T in…
- Trial name
- NCT00192257
- Testing
- CAIV-T and TIV
- Where
- 2 sites in Belgium
- Volunteers
- 2,229 people
- Sponsor
- MedImmune LLC
Influenza, Vaccination Adverse Event
A Post-marketing Safety Study of Inactivated, Split-virion Influenza Vaccine in Subjects Aged 3 Years and Older
To monitor the safety of Shanghai Institute of Biological Products Company's influenza vaccine in subjects aged 3 years and older through Adverse Events Following Immunization Surveillance System of China.
- Trial name
- NCT02133456
- Volunteers
- 166,240 people, healthy volunteers welcome
- Sponsor
- Centers for Disease Control and Prevention, China
Healthy
Study To Evaluate the Safety of Bivalent Vaccine
To assess the safety of a bivalent vaccine of two new influenza virus reassortants in healthy adults prior to the release of the trivalent vaccine (FluMist) containing them.
- Trial name
- NCT00325481
- Testing
- FluMist
- Where
- 3 sites in United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Healthy
Open-label Study to Assess Immunogenicity and Safety of a Vaccine Enhancement Patch When Administered With 2 Doses of H5N1 Vaccine
Groups 1 to 3 will receive two vaccinations on Day 0 and Day 21. Group 1 will receive 3.8µg A/H5N1 antigen formulated with AS03 adjuvant, administered by IM injection. Group 2 will receive 15µg A/H5N1 by IM alone.
- Trial name
- NCT01353534
- Testing
- A/H5N1 Antigen, Vaccine Enhancement Patch
- Where
- 5 sites in Austria, Belgium
- Volunteers
- 276 people, healthy volunteers welcome
- Sponsor
- Intercell USA, Inc.
Influenza
Evaluation the Safety and Tolerance of GP681 Tablets in Healthy Subjects
Influenza (influenza for short) is an acute respiratory infectious disease caused by influenza virus. The symptoms of the disease range from mild, moderate to severe, and severe cases require hospitalization and may die.
- Trial name
- NCT04729764
- Testing
- GP681 Tablet
- Where
- China
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Seasonal Influenza
Study to Evaluate Safety and Immunogenicity of Sub-unit Adjuvanted Influenza Vaccine Administered to Elderly Subjects, Formulation 2011-2012
This study will evaluate the safety and immunogenicity of a sub-unit, adjuvanted Influenza Vaccine Administered to Elderly Subjects.
- Trial name
- NCT01344057
- Testing
- Seasonal Influenza Vaccine
- Where
- 6 sites in Italy
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Upper Respiratory Infection
BD Veritor™ At-Home and BD Veritor™ Professional
The BD Veritor™ System is a rapid test that is testing for both COVID-19 and for Influenza This study will try to determine if the BD Veritor™ system can assist in the diagnosis of someone who has upper respiratory infection…
- Trial name
- NCT05352581
- Testing
- BD Veritor At-Home, BD Veritor Professional
- Where
- 17 sites in United States, Australia and 1 more
- Volunteers
- 1,146 people
- Sponsor
- Becton, Dickinson and Company
Influenza
Evaluate Safety & Immunogenicity of a Pandemic Influenza Vaccine (GSK1562902A) in Adults Over 60 Years of Age
The present study is designed to evaluate the immunogenicity and safety of a single or double dose of the pandemic influenza candidate vaccine (GSK1562902A), administered following a two-administration schedule (21 days apart) in…
- Trial name
- NCT00397215
- Testing
- Pandemic influenza vaccine (GSK1562902A) (adjuvanted or not), Fluarix
- Where
- 12 sites in Belgium, Italy
- Volunteers
- 437 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
SARS CoV 2 Infection, Influenza, Human
A Phase II Trial to Evaluate the Safety and Immunogenicity of BIMERVAX® When Coadministered With Seasonal Influenza Vaccine (SIIV) in Adults Older Than 65 Years of Age Fully Vaccinated Against COVID-19
This is a Phase II, randomized, double-blind, multi-centre trial to evaluate the safety and immunogenicity of BIMERVAX® when coadministered with seasonal surface antigen inactivated adjuvanted influenza vaccine (SIIV) in adults…
- Trial name
- NCT05981846
- Testing
- BIMERVAX, SIIV
- Where
- 8 sites in Spain
- Volunteers
- 279 people, healthy volunteers welcome
- Sponsor
- Hipra Scientific, S.L.U
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.